Home
Live Updates
Bivictrix selects final sequences for lead tumour programme : comparemela.com
Bivictrix selects final sequences for lead tumour programme
Bivictrix Therapeutics PLC - Macclesfield, England-based biotechnology company focused on cancer therapies - Says final sequences have been selected for its second programme BVX002, an antibody drug...
Related Keywords
Emma Curzon ,
Alliance News ,
Bivictrix Therapeutics ,
Alliance News Ltd ,
Executive Officer Tiffany Thorn ,
Acute Myeloid Leukaemia ,
All Rights ,
Markets ,
comparemela.com © 2020. All Rights Reserved.